Inflammation and atherosclerosis in rheumatoid arthritis

Expert Reviews in Molecular Medicine

Volumn 7, Issue 7, 2005, Pages

  Stevens, Robert J ^a   Douglas, Karen M J ^a   Saratzis, Athanasios N ^a   Kitas, George D ^a  

^a The Guest Hospital   (United Kingdom)

Author keywords

Atherosclerosis; C reactive protein; Cardiovascular disease; Inflammation; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SALAZOSULFAPYRIDINE; TYPHOID VACCINE; CYTOKINE; HEAT SHOCK PROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RUPTURE; VASCULITIS; ANIMAL; DISEASE COURSE; DISEASE MODEL; INFECTION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEAT-SHOCK PROTEINS; HUMANS; INFECTION; INFLAMMATION; LIPOPROTEINS, LDL; MICE; MYOCARDIAL ISCHEMIA; PREVALENCE; RISK FACTORS; RUPTURE, SPONTANEOUS;

EID: 31044434279     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399405009154     Document Type: Review

References (197)

1. Symmons, D. et al. (2002) The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41, 793-800
2. Goodson, N. (2002) Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 14, 115-120
3. Van Doornum, S., McColl, G. and Wicks, I.P. (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46, 862-873
4. Gabriel, S.E., Crowson, C.S. and O'Fallon, W.M. (1999) Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 26, 2529-2533
5. Pincus, T. and Callahan, L.F. (1992) Rheumatology function tests: grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol 19, 1051-1057
6. Pincus, T. and Callahan, L.F. (1986) Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 13, 841-845
7. Kitas, G.D. and Erb, N. (2003) Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42, 607-613
8. Linos, A. et al. (1980) The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 111, 87-98
9. Allebeck, P., Ahlbom, A. and Allander, E. (1981) Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate. Eleven-year follow-up of an epidemiological study. Scand J Rheumatol 10, 301-306
10. Vandenbroucke, J.P., Hazevoet, H.M. and Cats, A. (1984) Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 11, 158-161
11. Reilly, P.A. et al. (1990) Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 49, 363-369
12. Jacobsson, L.T. et al. (1993) Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 36, 1045-1053
13. Wolfe, F. et al. (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37, 481-494
14. Myllykangas-Luosujarvi, R. et al. (1995) Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol 22, 1065-1067
15. Callahan, L.F. et al. (1997) Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 10, 381-394
16. Wallberg-Jonsson, S., Ohman, M.L. and Dahlqvist, S.R. (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24, 445-451
17. Symmons, D.P. et al. (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25, 1072-1077
18. Lindqvist, E. and Eberhardt, K. (1999) Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 58, 11-14
19. Sokka, T., Mottonen, T.and Hannonen, P. (1999) Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. Scand J Rheumatol 28, 282-287
20. Kroot, E.J. et al. (2000) No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 59, 954-958
21. Kvalvik, A.G., Jones, M.A. and Symmons, D.P. (2000) Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol 29, 29-37
22. Riise, T. et al. (2001) Total mortality is increased in rheumatoid arthritis. A 17-year prospective study Clin Rheumatol 20, 123-127
23. Chehata, J.C. et al. (2001) Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 40, 447-452
24. Peltomaa, R. et al. (2002) Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 61, 889-894
25. Mikuls, T.R. et al. (2002) Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 61, 994-999
26. Bjornadal, L. et al. (2002) Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol 29, 906-912
27. Gabriel, S.E. et al. (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48, 54-58
28. Ward, M.M. (2001) Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 44, 1467-1469
29. Kitas, G., Banks, M.J. and Bacon, P.A. (2001) Cardiac involvement in rheumatoid disease. Clin Med 1, 18-21
30. McEntegart, A. et al. (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 40, 640-644
31. Erb, N. et al. (2004) Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 33, 293-299
32. Mutru, O. et al. (1989) Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 76, 71-77
33. Gabriel, S.E., Crowson, C.S. and O'Fallon, W.M. (1999) Comorbidity in arthritis. J Rheumatol 26, 2475-2479
34. del Rincon, I.D. et al. (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44, 2737-2745
35. Banks, M. et al. (2000) Rheumatoid arthritis is an independent risk factor for ischaemic heart disease {abstract}. Arthritis Rheum 43, S385
36. Wislowska, M., Sypula, S. and Kowalik, I. (1998) Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 17, 369-377
37. Jonsson, S.W. et al. (2001) Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol 28, 2597-2602
38. Kumeda, Y. et al. (2002) Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 46, 1489-1497
39. Park, Y.B. et al. (2002) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46, 1714-1719
40. Alkaabi, J.K. et al. (2003) Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 42, 292-297
41. Klocke, R. et al. (2003) Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 62, 414-418
42. Liuzzo, G. et al. (2000) Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101, 2883-2888
43. Nakajima, T. et al. (2003) De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res 93, 106-113
44. Gerli, R. et al. (2004) CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109, 2744-2748
45. Ross, R. (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340, 115-126
46. Raitakari, O.T. and Celermajer, D.S. (2000) Flow-mediated dilatation. Br J Clin Pharmacol 50, 397-404
47. Jansson, J.H., Nilsson, T.K. and Johnson, O. (1991) von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 66, 351-355
48. Farsi, A. et a]. (2001) Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. Atherosclerosis 154, 429-436
49. Hoffmann, U. et al. (2002) Relation of peripheral flow-mediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia. Am J Cardiol 90, 70-73
50. Felmeden, D.C. et al. (2003) A comparison of flow-mediated dilatation and von Willebrand factor as markets of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Blood Coagul Fibrinolysis 14, 425-431
51. Ihlemann, N., Stokholm, K.H. and Eskildsen, P.C. (2002) Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated Type 2 diabetes. Diabet Med 19, 476-481
52. Benjamin, E.J. et al. (2004) Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 109, 613-619
53. Tiefenbacher, C.P. et al. (2004) ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol 286, H1425-1432
54. Vallance, P. and Chan, N. (2001) Endothelial function and nitric oxide: clinical relevance. Heart 85, 342-350
55. Fichtlscherer, S. et al. (2000) Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102, 1000-1006
56. Venugopal, S.K. et al. (2002) Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106, 1439-1441
57. Hingorani, A.D. et al. (2000) Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102, 994-999
58. Vaudo, G. et al. (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63, 31-35
59. El-Magadmi, M. et al. (2004) Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110, 399-404
60. Filer, A.D. et al. (2003) Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 62, 162-167
61. Stary, H.C. (1989) Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 9, I19-32
62. Lucas, A.D. and Greaves, D.R. (2001) Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med 2001, 1-18
63. Smith, S.C., Jr. (1996) Risk-reduction therapy: the challenge to change. Presented at the 68th scientific sessions of the American Heart Association November 13, 1995 Anaheim, California. Circulation 93, 2205-2211
64. Lee, R.T. and Libby, P. (1997) The unstable atheroma. Arterioscler Thromb Vasc Biol 17, 1859-1867
65. Jonasson, L. et al. (1985) Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 76, 125-131
66. Stemme, S., Holm, J. and Hansson, G.K. (1992) T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 12, 206-211
67. Yla-Herttuala, S. et al. (1991) Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 88, 5252-5256
68. Nelken, N.A. et al. (1991) Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88, 1121-1127
69. Gosling, J. et al. (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103, 773-778
70. Frostegard, J. et al. (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33-43
71. Ludewig, B. et al. (2000) Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci U S A 97, 12752-12757
72. Geng, Y.J. et al, (1996) Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 16, 19-27
73. Kaartinen, M., Penttila, A. and Kovanen, P.T. (1994) Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90, 1669-1678
74. Bobryshev, Y.V. and Lord, R.S. (1995) S-100 positive cells in human arterial intima and in atherosclerotic lesions. Cardiovasc Res 29, 689-696
75. Yasojima, K. et al. (2001) Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158, 1039-1051
76. Zwaka, T.P., Hombach, V. and Torzewski, J. (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103, 1194-1197
77. Pasceri, V., Willerson, J.T. and Yeh, E.T. (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102, 2165-2168
78. Torzewski, M. et al. (2000) C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 20, 2094-2099
79. Nakajima, T. et al. (2002) T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105, 570-575
80. Kohchi, K. et al. (1985) Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy. Circulation 71, 709-716
81. van der Wal, A.C. et al. (1994) Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89, 36-44
82. Laine, P. et al. (1999) Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99, 361-369
83. van der Wal, A.C. et al. (1998) Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 80, 14-18
84. Hansson, G.K. et al. (1989) Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med 170, 1595-1608
85. Amento, E.P. et al. (1991) Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11, 1223-1230
86. de Beer, F.C. et al. (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47, 239-243
87. Liuzzo, G. et al. (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331, 417-424
88. Morrow, D.A. and Ridker, P.M. (2000) C-reactive protein, inflammation, and coronary risk. Med Clin North Am 84, 149-161, ix
89. Haverkate, F. et al. (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349, 462-466
90. Danesh, J. et al. (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Bmj 321, 199-204
91. Danesh, J. et al. (1999) Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 20, 954-959
92. Danesh, J. et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350, 1387-1397
93. Pillarisetti, S. et al. (1997) Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 100, 867-874
94. Grainger, D.J. et al. (1994) Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 370, 460-462
95. Poon, M. et al. (1997) Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 96, 2514-2519
96. Danesh, J., Collins, R. and Peto, R. (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102, 1082-1085
97. Thompson, S.G. et al. (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332, 635-641
98. Maresca, G. et al. (1999) Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 19, 1368-1377
99. Stec, J.J. et al. (2000) Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102, 1634-1638
100. Sechi, L.A. et al. (2000) Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 36, 978-985
101. Ridker, P.M., Buring, J.E. and Rifai, N. (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103, 491-495
102. Ridker, P.M. et al. (1998) Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351, 88-92
103. de Lemos, J.A., Hennekens, C.H. and Ridker, P.M. (2000) Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 36, 423-426
104. Ridker, P.M. et al. (2000) Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101, 2149-2153
105. Biasucci, L.M. et al. (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99, 2079-2084
106. Ridker, P.M. et al. (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101, 1767-1772
107. Wu, A.H. and Tsongalis, G.J. (2001) Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 87, 1361-1366
108. Boushey, C.J. et al. (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Jama 274, 1049-1057
109. van den Brandhof, W.E. et al. (2001) The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 157, 403-409
110. Hajjar, K.A. (1993) Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91, 2873-2879
111. Chambers, J.C. et al. (2001) Homocysteine - a novel risk factor for vascular disease. J R Soc Med 94, 10-13
112. Ma, J. et al. (1996) Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94, 2410-2416
113. Nygard, O. et al. (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337, 230-236
114. Ullegaddi, R., Powers, H.J. and Gariballa, S.E. (2004) B-group vitamin supplementation mitigates oxidative damage after acute ischaemic stroke. Clin Sci (Lond) 107, 477-484
115. Klerk, M. et al. (2002) MTHFR 677C - >T polymorphism and risk of coronary heart disease: a meta-analysis. Jama 288, 2023-2031
116. Stampfer, M.J. et al. (1992) A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. Jama. 268, 877-881
117. Whittle, S.L. and Hughes, R.A. (2004) Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 43, 267-271
118. Yxfeldt, A. et al. (2003) Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol 32, 205-210
119. van Ede, A.E. et al. (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41, 658-665
120. Choi, H.K. et al. (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359, 1173-1177
121. Erb, N. and Kitas, G.D. (2001) Homocysteine modulation as a reason for continuous folic acid supplementation in methotrexate-treated rheumatoid arthritis patients. Rheumatology (Oxford) 40, 715-716
122. Nunes, G.L. et al. (1997) Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation 96, 3593-3601
123. Carew, T.E., Schwenke, D.C. and Steinberg, D. (1987) Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 84, 7725-7729
124. Zhou, X. et al. (2001) LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21, 108-114
125. Nicoletti, A. et al. (2000) Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knockout mice. Mol Med 6, 283-290
126. Wu, R. et al. (1997) Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 17, 3159-3163
127. Hightower, L.E. (1991) Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 66, 191-197
128. Welch, W.J. (1993) How cells respond to stress. Sci Am 268, 56-64
129. Kleindienst, R. et al. (1993) Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 142, 1927-1937
130. Xu, Q. et al. (1992) Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 12, 789-799
131. George, J. et al. (1999) Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Throm Vasc Biol 19, 505-510
132. Afek, A. et al. (2000) Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 14, 115-121
133. Xu, Q. et al. (1999) Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study Circulation 100, 1169-1174
134. Hoppichler, F. et al. (1996) Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. Atherosclerosis 126, 333-338
135. Frostegard, J. et al. (1997) Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 29, 40-44
136. Xu, Q. et al. (1994) Surface staining and cytotoxic activity of heat-shock protein 60 antibody in stressed aortic endothelial cells. Circ Res 75, 1078-1085
137. Pockley, A.G. et al. (2000) Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 36, 303-307
138. Hochleitner, B.W. et al. (2000) Fluid shear stress induces heat shock protein 60 expression in endothelial cells in vitro and in vivo. Arterioscler Thromb Vasc Biol 20, 617-623
139. Zhu, W. et al. (1994) Oxidized-LDL induce the expression of heat shock protein 70 in human endothelial cells. Biochem Biophys Res Commun 200, 389-394
140. Kol, A. et al. (1999) Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103, 571-577
141. Maass, M. et al. (1998) Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 31, 827-832
142. Kalayoglu, M.V. and Byme, G.I. (1998) A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 66, 5067-5072
143. Halme, S. et al. (1999) Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest 29, 546-552
144. Kol, A. et al. (1998) Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98, 300-307
145. Espinola-Klein, C. et al. (2002) Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 105, 15-21
146. Ridker, P.M. et al. (2001) A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men. Ann Intern Med 135, 184-188
147. Danesh, J. et al. (2000) Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. Bmj 321, 208-213
148. Danesh, J. et al. (2002) Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J 23, 371-375
149. Mikuls, T.R. and Saag, K.G. (2001) Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 27, 283-303
150. Collins, R. et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335, 827-838
151. Sung, K.C. et al. (2003) High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 16, 429-433
152. Rueckschloss, U. et al. (2002) Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22, 1845-1851
153. Kugi, M. et al. (2002) Antioxidative effects of fluvastatin on superoxide anion activated by angiotensin II in human aortic smooth muscle cells. Cardiovasc Drugs Ther 16, 203-207
154. Costanzo, A. et al. (2003) Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 195, 402-410
155. Phillips, M.I. and Kagiyama, S. (2002) Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 3, 569-577
156. Wallberg-Jonsson, S. et al. (1999) Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 26, 2562-2571
157. Saito, M. et al. (2003) Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167, 73-79
158. Ponthieux, A. et al. (2004) Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis 172, 299-308
159. Situnayake, R.D. and Kitas, G. (1997) Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 56, 341-342
160. Svenson, K.L. et al. (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 147, 1912-1916
161. Lakatos, J. and Harsagyi, A. (1988) Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 21, 93-96
162. Lazarevic, M.B. et al. (1992) Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 22, 172-178
163. Lee, Y.H. et al. (2000) Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 19, 324-325
164. Boers, M. et al. (2003) Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62, 842-845
165. Mantel-Teeuwisse, A.K. et al. (2001) Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 24, 443-456
166. Powrie, J.K. et al. (1993) Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism 42, 415-419
167. Munro, R. et al. (1997) Effects of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 56, 374-377
168. Tam, L.S. et al. (2000) Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27, 2142-2145
169. McCarey, D.W. et al. (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021
170. Svenson, K.L. et al. (1987) Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 36, 940-943
171. Paolisso, G. et al. (1991) Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 40, 902-907
172. Ziccardi, P. et al. (2002) Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105, 804-809
173. Tchernof, A. et al. (2002) Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105, 564-569
174. Sattar, N. et al. (2003) Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-2963
175. Bergholm, R. et al. (2002) Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 22, 1637-1641
176. Kitas, G.D., Banks, M.J. and Bacon, P.A. (1998) Accelerated atherosclerosis as a cause of cardiovascular death in RA. Pathogenesis 1, 73-83
177. Pasceri, V. and Yeh, E.T. (1999) A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100, 2124-2126
178. Jacobsson, L.T. et al. (2001) Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 44, 1170-1176
179. Mitchell, D.M. et al. (1986) Survival, proposis, and causes of death in rheumatoid arthritis. Arthritis Rheum 29, 706-714
180. Lehtinen, K. and Isomaki, H. (1991) Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. J Rheumatol 18, 524-529
181. Krause, D. et al. (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43, 14-21
182. Landewe, R.B. et al. (2000) Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 355, 1616-1617
183. Hurlimann, D. et al. (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106, 2184-2187
184. Williams, B. et al. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Bmj 328, 634-640
185. Watson, D.J. et al. (2002) Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162, 1105-1110
186. Pratico, D. et al. (2001) Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A 98, 3358-3363
187. Ko, D. et al. (2002) Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J 143, 475-481
188. Ray, W.A. and Murray, K.T. (2002) Aspirin: redundant in users of nonaspirin, nonsteroidal antiinflammatory agents? Am Heart J 143, 381-382
189. Catella-Lawson, F. et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345, 1809-1817
190. Hennan, J.K. et al. (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104, 820-825
191. Lipsky, P.E. et al. (2000) Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 160, 913-920
192. FitzGerald, G.A. (2002) Cardiovascular pharmacology of nonselective nonsteroidal antiinflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89, 26D-32D
193. Bombardier, C. et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343, 1520-1528, 1522 p following 1528
194. Mukherjee, D., Nissen, S.E. and Topol, E.J. (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama 286, 954-959
195. Oberholzer-Gee, F. and Inamdar, S.N. (2004) Merck's recall of rofecoxib - a strategic perspective. N Engl J Med 351, 2147-2149
196. Daugherty, A. (2002) Mouse models of atherosclerosis. Am J Med Sci 323, 3-10
197. Leung, B.P. et al. (2003) A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol 170, 1524-1530